Haleon plc (HLNCF)
Healthcare · PNK
Price as at 1 Oct 2026, 01:24 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Haleon plc trades at $4.32, which is 123% below the $9.63 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 63 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 20.0 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
HLNCF dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.097 | 2 |
| 2025 | $0.090 | 2 |
| 2024 | $0.082 | 2 |
| 2023 | $0.056 | 2 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
HLNCF passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
HLNCF peers
The largest companies in the same industry (Drug Manufacturers - Specialty & Generic), then in the same sector.
- TKPHF Takeda Pharmaceutical Company Limited
- GALDY Galderma Group AG
- JHPCY JHPCY
- TEVA Teva Pharmaceutical Industries Limited
- UTHR United Therapeutics Corporation
- VTRS Viatris Inc.
- NBIX Neurocrine Biosciences, Inc.
- ELAN Elanco Animal Health Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Haleon plc (HLNCF) undervalued?
Against our fair value estimate of $9.63, HLNCF at $4.32 is 123% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is HLNCF's P/E ratio?
HLNCF trades at 20.0 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Haleon plc (HLNCF) pay a dividend?
Yes. Haleon plc yields 1.98% at the current share price. It has paid $0.097 per share over the trailing twelve months. It has paid a dividend in each of the last 3 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its HLNCF data?
Fundamentals for HLNCF come from company filings and exchange data, as listed on PNK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:24 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for HLNCF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.